AstraZeneca boosts heart, kidney business with $1.8B CinCor deal

By Reuters
| January 09, 2023

(Reuters) - AstraZeneca said Monday it had struck a deal to buy U.S.-based drug developer CinCor Pharma Inc. for up to $1.8 billion to increase its stock of heart and kidney drugs.

Full story

#1

Physicians are in short supply. They are costly. Is the APP the answer to the CMO's workforce and budget challenges? ...

Amid the hype and promise, a growing tension is becoming clear: the reality of what AI can deliver versus what it can't. ...